Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 12;9(15):4037-4042.
doi: 10.1182/bloodadvances.2025016680.

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

Christina Poh  1   2 , Jenna M Voutsinas  2 , Mazyar Shadman  1   2 , Ryan C Lynch  1   2 , Edus H Warren  1   2 , Caitlin A Crimp  2   3 , Brian G Till  1   2 , Chaitra S Ujjani  1   2 , Mengyang Di  1   2 , Vikram Raghunathan  1   2 , Stephen D Smith  1   2 , Qian V Wu  2 , Michi M Shinohara  2   3 , Ajay K Gopal  1   2
Affiliations

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

Christina Poh et al. Blood Adv. .

Abstract

Cytotoxic cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of T-cell lymphomas with variable prognoses and no standard of care. We identified patients with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL), primary cutaneous γδ T-cell lymphoma (PCGDTL), and subcutaneous panniculitis-like T-cell lymphoma (SPTCL), who were treated with ≥1 dose of pralatrexate between 2015 and 2024 at the University of Washington/Fred Hutchinson Cancer Center. Eighteen patients met criteria, 3 with CD8+ PCAETL, 6 with PCGDTL, and 9 with SPTCL. The median number of prior systemic therapies was 1 (range, 0-4), and the median pralatrexate treatment duration was 14 (range, 8-43) weeks. The overall response rate was 100%, with 12 (67%) achieving complete response (CR). Median duration of progression-free survival and overall survival was 5.6 months and not reached, respectively. Among patients who achieved CR , the median response duration was 22 months. At a median follow-up of 45 months, 6 (33%) patients remain in sustained remission. This retrospective analysis is the first to evaluate pralatrexate's efficacy in this aggressive disease population, demonstrating its effectiveness and association with durable responses in cytotoxic CTCL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
PFS of pralatrexate in cytotoxic CTCL.
Figure 2.
Figure 2.
OS of pralatrexate in cytotoxic CTCL.
Figure 3.
Figure 3.
Patient response to pralatrexate treatment.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. - PMC - PubMed
    1. Virmani P, Myskowski PL, Pulitzer M. Unusual variants of mycosis fungoides. Diagn Histopathol. 2016;22(4):142–151. - PMC - PubMed
    1. Willemze R, Jansen PM, Cerroni L, et al. EORTC Cutaneous Lymphoma Group Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838–845. - PubMed
    1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood. 2019;134(13):1112] Blood. 2019;133(16):1703–1714. - PMC - PubMed
    1. Geller S, Myskowski PL, Pulitzer M, Horwitz SM, Moskowitz AJ. Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chin Clin Oncol. 2019;8(1):5. - PubMed

MeSH terms

Substances